Imvax Advances a New Approach to Personalized Cancer Immunotherapy
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
Glioblastoma
Results:
Your Long-Time Brain Tumor Champion Ups Its Game in Washington
With the reigniting of the White House’s Cancer Moonshot Initiative, the ABTA recently joined the Brain Cancers Forum in Washington, D.C., to discuss opportunities in discovering treatments for brain cancers, including GBM.
Coping with a GBM Diagnosis: Developing a Routine
**Sponsored Content**
After processing the initial shock of her GBM diagnosis at 36, Jeanneane M. created a “coping routine” that’s helped her get through difficult days and hold onto hope for her future.
“Doing Hard Things” Community Bands Together to Drive Kelli McLaughlin’s Legacy Forward
Family and friends of Kelli McLaughlin are doing the hardest things: turning their grief into action to carry on Kelli’s legacy and vision of a future without brain tumors.
Neurosurgeon Brings One-of-a-Kind Imaging Technology to Puerto Rico to Advance Brain Tumor Surgery
**Sponsored Content** Meet one neurosurgeon who hopes to transform brain tumor care by bringing state-of-the-art technology to his homeland of Puerto Rico.
David Hou Awarded 2022 ABTA Lucien Rubinstein Award for ‘B Cell Vaccine Promotes Anti-Glioma Immunity Through Modulating CD8+ T Cells’
David Hou is awarded for his research on leveraging a B cell vaccine to improve immunotherapy treatment for GBM.
A Targeted Solution in Glioblastoma Treatment
**Sponsored Content**
For adult patients with recurrent GBM, a new clinical trial may offer access to emerging solutions and novel therapies unavailable elsewhere.
Research Update: DCVax-L Phase 3 Clinical Trial Data Published for GBM
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
2023: We’re Better Together
As we welcome 2023, it’s a time to embrace the new year and new ways to get involved and make an impact in the brain tumor community.
